Ti- cagrelor has not been studied in elective PCI or in patients who received fibrinolytic therapy; thus, no recommendations about its use in these clinical settings can be made. 5.7.3. IV Antiplatelet Therapy: Recommendations STEMI Class IIa 1. In patients undergoing primary PCI treated with UFH, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban), whether or not patients were pretreated with clopidogrel.584 590 (For GP IIb/IIIa inhibitor administration in patients not pre- treated with clopidogrel, Level of Evidence: A; for GP IIb/IIIa inhibitor administration in patients pretreated with clopidogrel, Level of Evidence: C) Class IIb 1. In patients undergoing primary PCI with abcix- imab, it may be reasonable to administer intracoro- nary abciximab.589,591 604 (Level of Evidence: B) Class III: NO BENEFIT 1. Routine precatheterization laboratory (eg, ambu- lance or emergency department) administration of GP IIb/IIIa inhibitors as part of an upstream strat- egy for patients with STEMI undergoing PCI is not beneficial.605 612 (Level of Evidence: B) UA/NSTEMI Class I 1. In UA/NSTEMI patients with high-risk features (eg, elevated troponin level) not treated with bivalirudin and not adequately pre-treated with clopidogrel, it is useful at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban) in patients treated with UFH.613 618 (Level of Evidence: A) Class IIa 1. In UA/NSTEMI patients with high-risk features (eg, elevated troponin level) treated with UFH and ade- quately pretreated with clopidogrel, it is reasonable at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban).616,619 (Level of Evidence: B) SIHD Class IIa 1. 